> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Expansion of Obesity Study
- URL: https://www.fdaweb.com/fda-oks-expansion-of-obesity-study/
- Published: 2020-06-19T12:00:00.000Z
- Updated: 2026-09-14T16:18:58.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5147053

FDA has approved the expansion of a USGI Medical pilot study of it endoscopic procedure known as [POSE 2.0](https://www.youtube.com/watch?time%5Fcontinue=1&v=7ATPkOF-rO0&feature=emb%5Flogo&ref=fdaweb.com). The study is designed to evaluate weight loss for adults suffering from obesity with a body mass index (BMI) of 35 to 40 kg and an obesity-related comorbidity, such as diabetes or hypertension. The procedure uses USGI Medical’s Incisionless Operating Platform to strategically place durable [Snowshoe Suture Anchors](http://endolumenalsurgery.com/eos/components-gcath.htm?ref=fdaweb.com) in gastric tissue to both shorten and narrow the stomach, according to the company. It provides volumetric gastric restriction, like that achieved by a surgical sleeve gastrectomy, without amputating part of the stomach, it says. “Patients treated with the POSE procedure typically return to work in just one to two days without any scars or signs of surgery.”  

During the first stage of the U.S. pilot study, patients evaluated at the midpoint follow-up of six months achieved on average 12.5% total body weight loss (TBWL). “All patients responded to treatment with a clinically meaningful TBWL greater than 5%, and 60% of patients achieved TBWL of greater than 13%,” USGI says.